Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantification of concentration and assessment of EGFR mutation in circulating DNA.

Cancer biomarkers : section A of Disease markers - 1 Jan 2015

Mazurek Agnieszka, Pierzyna Magdalena, Giglok Monika, Dworzecka Urszula, Suwiński Rafa, Ma Usecka Ewa

Abstract excerpt

BACKGROUND: Analysis of circulating cell-free DNA in blood is considered as a liquid biopsy, which enables non-invasive and repetitive investigation of the tumor DNA. The potential clinical usefulness of circulating DNA is frequently examined in lung cancer. Thus, our aim was assessment if chemotherapy influences the circulating DNA concentration. PATIENTS AND METHODS: Fifty-seven lung cancer patients in advanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA, Neoplasm
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EGFR gene

Share to TERT gene

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 25769456
DOI: 10.3233/CBM-150471
PMCID: PMC12965083

Genes

EGFR
TERT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantification of concentration and assessment of EGFR mutation in circulating DNA.PMID 25769456Read ↗

Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the diseaseSemantic proximity Read ↗

Allele frequency and proportion defined by circulating tumor DNA profiling predict tyrosine kinase inhibitors' therapeutic outcomes for non-small cell lung cancer.Semantic proximity Read ↗

Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectivesSemantic proximity Read ↗

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Circulating DNA: Diagnostic Tool and Predictive Marker for Overall Survival of NSCLC PatientsSemantic proximity Read ↗

[Determination of EGFR gene somatic mutations in tissues and plasma of patients with advanced non-small cell lung cancer].Semantic proximity Read ↗

Comparison of circulating DNA from plasma and urine for EGFR mutations in NSCLC patients.Semantic proximity Read ↗

Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis.Semantic proximity Read ↗

Circulating DNA and lung cancer.Semantic proximity Read ↗

Quantification of Free Circulating DNA As a Diagnostic Marker in Lung CancerSemantic proximity Read ↗

Circulating Cell-Free DNA in Plasma/Serum of Lung Cancer Patients as a Potential Screening and Prognostic ToolSemantic proximity Read ↗

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.